Last reviewed · How we verify

NCT07001904

Interleukin-6 in Plaque Psoriasis and Its Possible Role in Disease Severity

Completed Last updated 3 June 2025
What this trial tests

trial testing Enzyme-linked immunosorbent assay (ELISA) in Interleukin-6 in 50 participants. Completed in 31 October 2024.

Timeline
1 November 2023
Primary endpoint
31 October 2024
31 October 2024

Quick facts

Lead sponsorTanta University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date1 November 2023
Primary completion31 October 2024
Estimated completion31 October 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

18 and older, any sex, with Interleukin-6 or Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to evaluate serum IL-6 levels in plaque psoriasis patients and investigate their correlation with disease severity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07001904.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing